ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Amgen, AstraZeneca and Hansoh Pharmaceutical Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Amgen×AstraZeneca×Hansoh Pharmaceutical Group×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AmgenAstraZenecaHansoh Pharmaceutical Group
studies on the registry1,0884,197190
open to participants now50298117
phase 3 studies under way5020021
reach primary completion within a year3516827
programswith a study of their own in two years24119+5 named only42

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAmgenAstraZenecaHansoh Pharmaceutical Group
Phase 1

Amgen: 8 of its 24 programs at phase 1

  1. AMG 691phase 1
  2. AMG 127phase 1
  3. etakafusp alfaphase 1
  4. Pan-KRAS Inhibitor AMG 410phase 1
  5. tambotatug pelitecanphase 1

and 3 more — sign in to see them all

33%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Hansoh Pharmaceutical Group: 19 of its 42 programs at phase 1

  1. HS-20122phase 1
  2. HS-20136-2phase 1
  3. PARP1 Inhibitor HS-10502phase 1
  4. Alveltamigphase 1
  5. apatinibphase 1

and 14 more — sign in to see them all

45%
Phase 2

Amgen: 1 of its 24 programs at phase 2

  1. AMG 732phase 2
4%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Hansoh Pharmaceutical Group: 9 of its 42 programs at phase 2

  1. HS-20118phase 2
  2. HIF-2alpha Inhibitor HS-10516phase 2
  3. HS-10390phase 2
  4. HS-10542phase 2
  5. RET Inhibitor HS-10365phase 2

and 4 more — sign in to see them all

21%
Phase 3

Amgen: 7 of its 24 programs at phase 3

  1. maridebart cafraglutidephase 3
  2. tarlatamabphase 3
  3. xaluritamigphase 3
  4. sotorasibphase 3
  5. olpasiranphase 3

and 2 more — sign in to see them all

29%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Hansoh Pharmaceutical Group: 13 of its 42 programs at phase 3

  1. risvutatug rezetecanphase 3
  2. HS-10504phase 3
  3. HS-10506phase 3
  4. aumolertinibphase 3
  5. mocertatug rezetecanphase 3

and 8 more — sign in to see them all

31%
Approved, new studies

Amgen: 8 of its 24 programs at approved, new studies

  1. inebilizumabapproved, new study
  2. blinatumomabapproved, new study
  3. apremilastapproved, new study
  4. evolocumabapproved, new study
  5. romiplostimapproved, new study

and 3 more — sign in to see them all

33%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Hansoh Pharmaceutical Group: 1 of its 42 programs at approved, new studies

  1. tenofovir amibufenamideapproved, new study
2%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Amgen12 readouts · 3 phase 3·

Amgen, Dec ’26: 1 program whose next study reaches primary completion

  1. sotorasibphase 3 · Dec 17 · NCT04185883

Amgen, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. AMG 732phase 2 · Jan 6 · NCT06401044
  2. apremilastapproved, new study · Jan 10 · NCT07908641
  3. romosozumabapproved, new study · Jan 14 · NCT07811999
  4. maridebart cafraglutidephase 3 · Jan 21 · NCT06858839

Amgen, Feb ’27: 1 program whose next study reaches primary completion

  1. xaluritamigphase 3 · Feb 17 · NCT06613100

Amgen, Mar ’27: 1 program whose next study reaches primary completion

  1. AMG 691phase 1 · Mar 17 · NCT07745907

Amgen, Apr ’27: 2 programs whose next study reaches primary completion

  1. inebilizumabapproved, new study · Apr 13 · NCT05549258
  2. tarlatamabphase 3 · Apr 24 · NCT06598306

Amgen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. evolocumabapproved, new study · May 29 · NCT05284747
·

Amgen, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. afliberceptphase 3 · Jul 31 · NCT07614776
··

Amgen, Oct ’27: 1 program whose next study reaches primary completion

  1. AMG 127phase 1 · Oct 2 · NCT07590193
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Hansoh Pharmaceutical Group15 readouts · 2 phase 3

Hansoh Pharmaceutical Group, Nov ’26: 1 program whose next study reaches primary completion

  1. HS-10504phase 3 · Nov 19 · NCT07685041

Hansoh Pharmaceutical Group, Dec ’26: 4 programs whose next study reaches primary completion

  1. HS-20118phase 2 · Dec 25 · NCT07896915
  2. risvutatug rezetecanphase 3 · Dec 30 · NCT06699576
  3. Anti-CDH17 Antibody-drug Conjugate HS-20110phase 2 · Dec 31 · NCT06892379
  4. HS-20136-2phase 1 · Dec 31 · NCT07483437

Hansoh Pharmaceutical Group, Jan ’27: 2 programs whose next study reaches primary completion

  1. HS-20152phase 1 · Jan 1 · NCT07503015
  2. HS-10522phase 1 · Jan 20 · NCT07609875

Hansoh Pharmaceutical Group, Feb ’27: 1 program whose next study reaches primary completion

  1. Embibatinibphase 3 · Feb 0 · NCT07933224

Hansoh Pharmaceutical Group, Mar ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. HS-20137phase 3 · Mar 1 · NCT07879885
  2. mocertatug rezetecanphase 3 · Mar 7 · NCT06855069
  3. olatorepatidephase 3 · Mar 30 · NCT07156500
·

Hansoh Pharmaceutical Group, May ’27: 2 programs whose next study reaches primary completion

  1. HS-10542phase 2 · May 30 · NCT07470762
  2. HS-10582phase 1 · May 30 · NCT07777003
·

Hansoh Pharmaceutical Group, Jul ’27: 1 program whose next study reaches primary completion

  1. HIF-2alpha Inhibitor HS-10516phase 2 · Jul 10 · NCT07097935

Hansoh Pharmaceutical Group, Aug ’27: 1 program whose next study reaches primary completion

  1. RET Inhibitor HS-10365phase 2 · Aug 31 · NCT06147570
··
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Amgen

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 5

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Hansoh Pharmaceutical Group

New programs 1

  • HS-20197phase 1 · first study · Sep 10

Reached a new phase 2

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 46 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionAmgenAstraZenecaHansoh Pharmaceutical Group
Carcinoma, Non-Small-Cell Lungall three · compare here

Amgen in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. sotorasibphase 3
  2. Pan-KRAS Inhibitor AMG 410phase 1
  3. tambotatug pelitecanphase 1
  4. romiplostimapproved, new study

Their studies: Amgen’s studies of Carcinoma, Non-Small-Cell Lung in search

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Hansoh Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. risvutatug rezetecanphase 3
  2. HS-10504phase 3
  3. aumolertinibphase 3
  4. HS-20117phase 3
  5. dalmelitinibphase 3

and 5 more — sign in to see them all

Their studies: Hansoh Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Prostatic Neoplasmsall three · compare here

Amgen in Prostatic Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. xaluritamigphase 3

Their studies: Amgen’s studies of Prostatic Neoplasms in search

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Hansoh Pharmaceutical Group in Prostatic Neoplasms: 3 programs

  1. risvutatug rezetecanphase 3
  2. Alveltamigphase 1
  3. HRS-5041phase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Prostatic Neoplasms in search

Neoplasmsall three · compare here

Amgen in Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. teprotumumabapproved, new study

Their studies: Amgen’s studies of Neoplasms in search

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Hansoh Pharmaceutical Group in Neoplasms: 5 programs

  1. risvutatug rezetecanphase 3
  2. mocertatug rezetecanphase 3
  3. dalmelitinibphase 3
  4. adebrelimabphase 2
  5. apatinibphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Neoplasms in search

Renal Insufficiency, Chronicall three · compare here

Amgen in Renal Insufficiency, Chronic: 1 program

  1. Pegloticaseapproved, new study

Their studies: Amgen’s studies of Renal Insufficiency, Chronic in search

AstraZeneca in Renal Insufficiency, Chronic: 8 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. Berzanoflastphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency, Chronic in search

Hansoh Pharmaceutical Group in Renal Insufficiency, Chronic: 1 program

  1. HS-10390phase 2

Their studies: Hansoh Pharmaceutical Group’s studies of Renal Insufficiency, Chronic in search

Small Cell Lung Carcinomaall three · compare here

Amgen in Small Cell Lung Carcinoma: 4 programs

  1. tarlatamabphase 3
  2. etakafusp alfaphase 1
  3. tambotatug pelitecanphase 1
  4. Zocilurtatug Pelitecanphase 1

Their studies: Amgen’s studies of Small Cell Lung Carcinoma in search

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

Hansoh Pharmaceutical Group in Small Cell Lung Carcinoma: 4 programs

  1. risvutatug rezetecanphase 3
  2. adebrelimabphase 2
  3. Alveltamigphase 1
  4. Platinum Compoundsphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Small Cell Lung Carcinoma in search

Diabetes Mellitus, Type 2all three · compare here

Amgen in Diabetes Mellitus, Type 2: 2 programs

  1. maridebart cafraglutidephase 3
  2. AMG 127phase 1

Their studies: Amgen’s studies of Diabetes Mellitus, Type 2 in search

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Hansoh Pharmaceutical Group in Diabetes Mellitus, Type 2: 1 program

  1. olatorepatidephase 3

Their studies: Hansoh Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

Obesityall three · compare here

Amgen in Obesity: 1 program

  1. maridebart cafraglutidephase 3

Their studies: Amgen’s studies of Obesity in search

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Hansoh Pharmaceutical Group in Obesity: 2 programs

  1. olatorepatidephase 3
  2. HS-20136-2phase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Obesity in search

Dyslipidemiasall three · compare here

Amgen in Dyslipidemias: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Dyslipidemias in search

AstraZeneca in Dyslipidemias: 3 programs

  1. laroprovstatphase 3
  2. AZD4954phase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Dyslipidemias in search

Hansoh Pharmaceutical Group in Dyslipidemias: 2 programs

  1. HS-10582phase 1
  2. rosuvastatinphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Dyslipidemias in search

Hyperlipidemiasall three · compare here

Amgen in Hyperlipidemias: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Hyperlipidemias in search

AstraZeneca in Hyperlipidemias: 3 programs

  1. laroprovstatphase 3
  2. Laroprovstat/ezetimibe FCDP-slow variantphase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hyperlipidemias in search

Hansoh Pharmaceutical Group in Hyperlipidemias: 1 program

  1. rosuvastatinphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Hyperlipidemias in search

Lymphoma, B-Cellall three · compare here

Amgen in Lymphoma, B-Cell: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Lymphoma, B-Cell in search

Hansoh Pharmaceutical Group in Lymphoma, B-Cell: 1 program

  1. rocbrutinibphase 2

Their studies: Hansoh Pharmaceutical Group’s studies of Lymphoma, B-Cell in search

Hypercholesterolemiaall three · compare here

Amgen in Hypercholesterolemia: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Hypercholesterolemia in search

AstraZeneca in Hypercholesterolemia: 2 programs

  1. laroprovstatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypercholesterolemia in search

Hansoh Pharmaceutical Group in Hypercholesterolemia: 1 program

  1. rosuvastatinphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Hypercholesterolemia in search

Pancreatic Neoplasmsall three · compare here

Amgen in Pancreatic Neoplasms: 1 program

  1. tambotatug pelitecanphase 1

Their studies: Amgen’s studies of Pancreatic Neoplasms in search

AstraZeneca in Pancreatic Neoplasms: 2 programs

  1. sonesitatug vedotinphase 3
  2. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Pancreatic Neoplasms in search

Hansoh Pharmaceutical Group in Pancreatic Neoplasms: 1 program

  1. adebrelimabphase 2

Their studies: Hansoh Pharmaceutical Group’s studies of Pancreatic Neoplasms in search

Show all 46

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Amgen 17 of 24 · AstraZeneca 68 of 119 · Hansoh Pharmaceutical Group 29 of 42 programs (54 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).